JP2023001065A - ニコチンアミドモノヌクレオチド-イソニコチノイド共結晶およびその組成物 - Google Patents
ニコチンアミドモノヌクレオチド-イソニコチノイド共結晶およびその組成物 Download PDFInfo
- Publication number
- JP2023001065A JP2023001065A JP2022094952A JP2022094952A JP2023001065A JP 2023001065 A JP2023001065 A JP 2023001065A JP 2022094952 A JP2022094952 A JP 2022094952A JP 2022094952 A JP2022094952 A JP 2022094952A JP 2023001065 A JP2023001065 A JP 2023001065A
- Authority
- JP
- Japan
- Prior art keywords
- nicotinamide mononucleotide
- crystal
- isonicotinoid
- crystals
- nmn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 229960003966 nicotinamide Drugs 0.000 title claims abstract description 31
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 31
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims description 5
- 239000013078 crystal Substances 0.000 claims abstract description 61
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 10
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000010586 diagram Methods 0.000 claims description 2
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 abstract description 34
- 239000003814 drug Substances 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000005855 radiation Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 8
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 7
- 229950006238 nadide Drugs 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000011049 filling Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
67gのβ-ニコチンアミドモノヌクレオチドおよび24gのイソニコチンアミドを2Lの水に溶解し、そしてその中に2Lのアセトンを徐々に滴下し、滴下しながら攪拌し、滴下過程において溶液の温度を30℃に保ち、滴下完了した後に、溶液の温度を8℃に下げ、結晶が析出するように静置して、結晶の析出が終わった後、溶液を濾過して、本発明によって提供されるニコチンアミドモノヌクレオチド-イソニコチノイド共結晶を得る。
それぞれ形態1の結晶、形態2の結晶、および実施例1~4で調製されたニコチンアミドモノヌクレオチド-イソニコチノイド共結晶を適量取り、200メッシュのスクリーンを通過し、カプセルシェルをカプセルプレートに固定し、ボディプレートに粉末製剤を充填し、ボディプレートに粉末を注ぎ、スクレーパで往復にこすり、カプセルシェルが粉末で満たされた後、ボディプレートの余分な粉末をこすり落とし、カプセルを得る。次に、「中華人民共和国薬典」(2020年版)を参照して、0103カプセル剤通則において、カプセル剤[充填量の差異]の検査方法については、充填されたカプセルを測定し、それぞれ形態1の結晶、形態2の結晶および実施例1~4の共結晶の各グループに対応する各粒の充填量を平均充填量と比較した後の充填量の差異平均値X(%)を算出し、各充填量の差異値の絶対値を求め、各グループの平均値 ̄Xを、式 ̄X=(X1+X2+…Xn)/nで算出し、結果を表3に示す。ここで、平均値を示すバー付きXを ̄Xで表す。
Claims (7)
- Cu-Kα照射、2θ角で示されるX-線粉末回折を使用し、9.6±0.2°、13.3±0.3°、22.8±0.2°および36.5±0.2°で回折ピークを有することを特徴とする、ニコチンアミドモノヌクレオチド-イソニコチノイド共結晶。
- Cu-Kα照射、2θ角度で示されるX-線粉末回折を使用し、9.6±0.2°、9.8±0.2°、10.6±0.2°、13.3±0.3°、16.3±0.2°、21.3±0.2°、22.8±0.2°、32.1±0.2°および36.5±0.2°で回折ピークを有することを特徴とする、請求項1に記載のニコチンアミドモノヌクレオチド-イソニコチノイド共結晶。
- 前記共結晶は、実質的に図1に示されるX-線粉末回折パターンを有することを特徴とする、請求項1に記載のニコチンアミドモノヌクレオチド-イソニコチノイド共結晶。
- 前記共結晶の示差走査熱量測定分析図において、55.8±3°Cと151.9±3°Cで吸熱ピークを有することを特徴とする、請求項1に記載のニコチンアミドモノヌクレオチド-イソニコチノイド共結晶。
- 前記共結晶は、実質的に図2に示される示差走査熱量測定分析図を有することを特徴とする、請求項1に記載のニコチンアミドモノヌクレオチド-イソニコチノイド共結晶。
- 請求項1~5のいずれか一項に記載のニコチンアミドモノヌクレオチド-イソニコチノイド共結晶を含むことを特徴とする、ニコチンアミドモノヌクレオチド組成物。
- 前記医薬品またはヘルスケア製品の有効成分は、請求項1~5のいずれか一項に記載のニコチンアミドモノヌクレオチド-イソニコチノイド共結晶を含むことを特徴とする、医薬品またはヘルスケア製品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110677784.1A CN113292619B (zh) | 2021-06-18 | 2021-06-18 | 烟酰胺单核苷酸-异烟碱共晶体及其组合物 |
CN202110677784.1 | 2021-06-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023001065A true JP2023001065A (ja) | 2023-01-04 |
JP7438512B2 JP7438512B2 (ja) | 2024-02-27 |
Family
ID=77328779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022094952A Active JP7438512B2 (ja) | 2021-06-18 | 2022-06-13 | ニコチンアミドモノヌクレオチド-イソニコチノイド共結晶およびその組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220402961A1 (ja) |
JP (1) | JP7438512B2 (ja) |
CN (1) | CN113292619B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114213485A (zh) * | 2021-12-31 | 2022-03-22 | 浙江拓普药业股份有限公司 | 一种烟酰胺单核苷酸结晶的制备方法 |
CN115368423A (zh) * | 2022-02-23 | 2022-11-22 | 音芙医药科技(上海)有限公司 | 还原型β-烟酰胺单核苷酸二钠盐的多晶型及其制法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2542881B (en) * | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
WO2018047715A1 (ja) * | 2016-09-06 | 2018-03-15 | 協和発酵バイオ株式会社 | β-ニコチンアミドモノヌクレオチドの結晶及びその製造方法 |
CN112538101A (zh) * | 2020-08-13 | 2021-03-23 | 常州博海威医药科技股份有限公司 | 一种β烟酰胺单核苷酸的新晶型及其制备方法和用途 |
-
2021
- 2021-06-18 CN CN202110677784.1A patent/CN113292619B/zh active Active
-
2022
- 2022-06-06 US US17/833,110 patent/US20220402961A1/en active Pending
- 2022-06-13 JP JP2022094952A patent/JP7438512B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CN113292619A (zh) | 2021-08-24 |
CN113292619B (zh) | 2022-04-22 |
US20220402961A1 (en) | 2022-12-22 |
JP7438512B2 (ja) | 2024-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7438512B2 (ja) | ニコチンアミドモノヌクレオチド-イソニコチノイド共結晶およびその組成物 | |
JP2023001064A (ja) | ニコチンアミドモノヌクレオチド共結晶を調製する方法 | |
CN104736526B (zh) | 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途 | |
Boksa et al. | Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion | |
JP7146741B2 (ja) | Egfr阻害剤の薬学的な塩及びその結晶形、製造方法並びに使用 | |
JP4187423B2 (ja) | ジプラシドン組成物 | |
WO2021136477A1 (zh) | 化合物i二盐酸盐的共晶及其制备方法和用途 | |
TW201247613A (en) | Ester derivatives of bimatoprost compositions and methods | |
JP2011516430A (ja) | ルビプロストン結晶、その製造方法および用途 | |
CN105873931B (zh) | 托法替布柠檬酸盐 | |
Shaikh et al. | Understanding solid-state processing of pharmaceutical cocrystals via milling: Role of tablet excipients | |
WO2021196951A1 (zh) | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 | |
CN108299267A (zh) | (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 | |
Nisar et al. | 11-Azaartemisinin cocrystals with preserved lactam: Acid heterosynthons | |
WO2018233437A1 (zh) | 巴瑞克替尼的晶型及其制备方法 | |
JP7466642B2 (ja) | レンバチニブメシル酸塩結晶形xi及びその調製方法 | |
WO2022262244A1 (zh) | 一种阿哌沙班的尿素共晶及其制备方法 | |
WO2021104021A1 (zh) | Tropifexor的新晶型及其制备方法 | |
TW460461B (en) | Substituted phenylamidines for use in fighting or preventing diseases in which smaller or larger cell aggregations occur or cell-matrix interactions are involved, pharmaceutical compositions containing these compounds and processes for preparing them | |
CN117285582A (zh) | 一种烟酰胺单核苷酸-脯氨酸共晶体及其组合物 | |
WO2020233226A1 (zh) | 四氢噻吩并吡啶化合物的b晶型及制法、组合物和应用 | |
WO2021259732A1 (en) | Multi-component compounds comprising zanubrutinib and a benzoic acid derivative | |
WO2014040280A1 (zh) | 哌拉西林钠与舒巴坦钠共晶及其制备方法、以及包含该共晶的药物组合物及其应用 | |
CN104447671B (zh) | 雏菊叶龙胆酮单晶及其制备方法与应用 | |
US20240010646A1 (en) | Urea Co-Crystal of Apixaban, and Preparation Method Therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20220629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220708 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20220812 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220812 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231109 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7438512 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |